Aims: To evaluate and compare the efficacy of Hilo® and Daflon® 500 mg, in the treatment of hemorrhoids. Study Design: It is a multicentric, randomized, comparative clinical trial conducted for the period of 15 days. Place and Duration of Study:
INTRODUCTION
Hemorrhoids are defined as the symptomatic enlargement and distal displacement of the normal anal cushions. The most common symptom of hemorrhoids is rectal bleeding associated with bowel movement. The abnormal dilatation and distortion of the vascular channel, together with destructive changes in the supporting connective tissue within the anal cushion, is a paramount finding of hemorrhoids [1] .
Approximately 40.7 million people in India are reported to suffer from hemorrhoids [2] . Hemorrhoidal symptoms are observed in about 60% of the patients suffering from hemorrhoids. The most common symptom of internal hemorrhoids is bleeding which can be painless and is bright red in color. The external hemorrhoids are more likely to be associated with pain, due to activation of perianal innervations associated with thrombosis. Patients typically describe a painful perianal mass that is tender to palpation. The other symptoms of hemorrhoids include: tenesmus, irritation of the skin surrounding the anus, soiling, itching, mucus discharge, sensation of tissue prolapse etc [3, 4] .
For the management of hemorrhoids, lifestyle changes and other non-operative measures have been recommended as first line therapy for management of hemorrhoids. These measures for hemorrhoids management are associated with significant improvement in the outcome scores reported by patients [5] .
Various other options are available which are classified as surgical management such as Hemorrhoidectomy, Stapled hemorrhoidopexy, Doppler-guided hemorrhoid artery ligation. Nonsurgical office procedures or minimally invasive procedures are also commonly used like Rubber band ligation, Sclerotherapy, Infrared coagulation, whereas the conservative management entailing treatment with phlebotonics, consumption of high fibre foods, psyllium husks, topical creams to relieve inflammation and pain, sitz bath, analgesics etc. is used for the symptomatic management of the hemorrhoids [3, 6] .
The medical and conservative management with high-fibre diets, stool softeners and laxatives are the preferred treatments for Grade I to Grade II hemorrhoids whereas surgical procedures are reserved for the more severe hemorrhoids [7] .
Phlebotonics are a heterogeneous group of drugs which are indicated for the treatment of chronic vein insufficiency and also for the management of less severe hemorrhoids. These drugs are helpful in the management of Grade-I, Grade-II as well as thrombosed hemorrhoids. Phlebotonics act by strengthening the vascular walls which increases the venous tone and improves lymphatic drainage thus normalises the capillary permeability. Phlebotonics are mostly natural products; e.g.: flavonoids, sapsonides, etc. The synthetic phlebotonics include: calcium dobesilate, naftazone, aminaftone, chromocarbe [8] .
Hilo® capsules are rich in flavonoid contents and act as phlebotonic with vascular-protecting properties.
Hilo® [10] .
Hilo® also acts on the lymphatic system and improves lymphatic drainage by increasing lymph flow and lymph oncotic pressure [11] . This action on the lymphatic system is associated with a venotonic and vasculoprotective effect thereby reducing edema. By virtue of its venotonic, vascular-protecting and anti-inflammatory action, Hilo® improves hemorrhoidal signs and symptoms e.g., anal discomfort, pain, redness, anal discharge, tenesmus, pruritus, erythema and bleeding. In addition to the above, it also significantly reduces the frequency, severity and duration of acute hemorrhoidal episodes and bleeding in all grades of hemorrhoids [12] .
Daflon® tablets are made from micronized purified flavonoid fraction consisting of 10% hesperidin and 90% diosmin. Daflon® also belongs to the phlebotonic category of drugs. Daflon® exerts its effect by increasing the venous tone, protecting the microcirculation against inflammatory process and improving the lymphatic drainage [10] . It is indicated clinically for the treatment of venous insufficiency and hemorrhoids [13] .
The present study was conducted to compare the efficacy and safety of Hilo® and Daflon® in the treatment of hemorrhoids.
MATERIALS AND METHODS

Study Design
This was a multicentric, randomized, open labelled, comparative study. All the patients were randomly assigned in a 1:1 ratio that is 101 patients in Hilo® group and 99 in Daflon® group respectively. The study was conducted as per the ICH GCP guidelines [14] and Schedule-Y of Indian Drugs and Cosmetics Act [15] . The respective institutional ethics committees of the trial sites approved the study protocol and other relevant documents before the enrolment of patients.
Participants
For inclusion in the study, the patients had to qualify the inclusion and exclusion criteria as per the approved protocol (attached as appendix). Adult patients of either gender diagnosed with hemorrhoids confirmed by proctoscopy were included in the study. All the eligible patients were provided with all the necessary information regarding the study and the investigational products and were asked to sign the informed consent form before proceeding with the patient enrolment in the study.
Patients using other anti-hemorrhoidal drugs or planning to undergo any surgical procedure for hemorrhoids and pregnant women, or lactating mothers were not included in the study.
This study was conducted at four centers in India-Janta Hospital and Maternity Centre, Varanasi; King George Memorial Hospital, Lucknow; Vijan Hospital and Research Centre, Nasik and Santosh Hospital, Bangalore.
Interventions
The enrolled patients were randomized to receive either of the two investigational products: Hilo® herbal capsules (2 caps twice daily), manufactured by Zuventus Healthcare Limited, India and Daflon® 500 mg (2 tablets daily), manufactured by Serdia Pharmaceuticals Private Limited, India.
Hilo® is a herbal preparation containing a mixture of four herbs, where each capsule contains Commiphora molmol (Heerabol) oleoresin (250 mg), Gardenia gummifera (Naadihingu) gum-resin (83 mg), and Tagates erecta (Genda) flowers (83.5 mg), and Mesua ferrea (Nagakesar) stem (83.5). It is standardized to contain not less than 7% of total catechins and epicatechins. Each Daflon® 500 mg tablet contains micronized purified flavonoid extracts of rutaceae 500 mg, equivalent to 450 mg of diosmin and 50 mg of hesperidine per tablet.
At the end of treatment regimen (Day 15), study medication containers were retrieved from the patients and the remaining tablets were counted. Thus the compliance was ensured by project staff through pill count. Any other antihemorrhoidal treatment or laxatives were not allowed during the trial period.
Outcomes
Primary outcome of the study was to evaluate an improvement in the intensity of hemorrhoidal symptoms and grades of hemorrhoids as observed with proctoscope on Day 15 by the investigator.
Secondary outcome was global assessment for overall improvement by patient and physician on Day 15 and number of adverse reactions reported by patients throughout the study duration.
Sample Size
A sample size of the study was calculated using a level of significance of 5% and a power of 90%. Following parameters were consideredConfidence level = 95% Acceptable difference = 0.10 Assumed proportion = 0.50
Using WINPEPI software, it was found that required sample size is 97 in each group.
The present study enrolled 200 patients, 100 patients in each group.
Randomisation
For allocation of the participants at various study centers, computer-generated randomization blocks were used. Participants were randomly assigned following a simple randomization procedure to either of the treatment groups. The randomization chart was prepared by a third party with no direct involvement in the study. Patients were screened and enrolled by the investigators based upon the eligibility criteria. Study medications were labelled and dispensed to trial patients by investigators as per the randomization chart.
Study Assesments
On day 0, screening and randomization of the patients was done. This involved signing of informed consent document and enrolment of patients as per the inclusion and exclusion criteria. Demographics and medical history including previous history of hemorrhoids or any other chronic diseases was assessed. The investigational products were dispensed to all eligible patients on day 0 as per the randomization scheme generated using SAS 9.1 software. The enrolled patients were given the investigational products for 15 days with instructions for drug administration.
Proctologic examination was performed to assess the hemorrhoidal conditions on day 0 and day 15 i.e. before the start of treatment and at the end of the study. Proctologic assessment was performed in the left-lateral position by inspection of the anal verge of the anal canal by using a proctoscope. Parameters namely, Grade (I, II, III, IV) and position of hemorrhoids (at one site, two sites or all three primary sites, i.e., 3'O clock, 7'O clock, 11'O clock position) were assessed. The severity of clinical symptoms of hemorrhoids (bleeding, pain, itching, soiling, tenesmus, irritation after defecation and constipation) was assessed using a 4-point scale: (0= absent, 1= mild, 2= moderate and 3= severe) on each visit i.e. day 0, day 7 and day 15. Additionally, on day 15, global assessment of the interventions was done subjectively by the patients as well as the investigators.
Statistical Assesment
The following null hypothesis was formulated:
Ho: There is no difference between the two treatment groups in improving the clinical symptoms of hemorrhoids H1: There is a difference between the two treatment groups in improving the clinical symptoms of hemorrhoids Analysis were performed using Stats Direct software (Version 3.1.22). The data are expressed as mean ± S.D. or percentage. Unpaired t-test was used to compare the demographic parameters of age, weight and height. Mann-Whitney U test was used for 'between the group' comparison while Wilcoxon's signed ranks test was used to compare the changes 'within the group' and McNemar and exact (Liddell) test was used to compare the proportions. 95% Confidence Interval (C.I.) for the true proportions were also calculated. All 'P values' were considered significant if less than .05.
The study protocol has been in given appendix.
RESULTS
In the present study, a total of 201 patients presenting with hemorrhoids were screened at 4 clinical trial sites. Out of the 201 patients screened, 200 fulfilled the eligibility criteria and were enrolled in the study. The patients were randomized to receive either Hilo® or Daflon® where the Hilo® group comprised of 99 patients while 101 patients were allotted in the Daflon® group. All 200 patients completed the study as per the approved protocol and their data was subjected to statistical analysis at the end of the study. A consort chart of trial participants is described in Fig. 1 
Demographics
On Day 0, the demographic parameters like age, height and weight were documented. The means of demographic parameters of age, weight and height were compared using unpaired t-test. The baseline individual symptom scores of the two treatment groups were compared using MannWhitney U test. No significant difference was observed between the two groups (P > .05) ( Table 1 ).
Assessment of Total Symptom Score and Individual Clinical Symptom Score
The total symptom score was calculated by adding the individual symptom scores of bleeding, pain, itching, soiling, tenesmus, irritation after defecation, constipation for each patient. The individual symptom scores of bleeding, pain, itching, soiling, tenesmus, irritation after defecation, constipation were scored for their severity on Day 0, Day 7 and Day 15. The mean change in the total symptom score and the individual clinical symptom score from the baseline score of Day 0 was evaluated at Day 7 and Day 15 using Wilcoxon's signed ranks test for both the groups (Table 2) . Mean change in total symptom score was found to be statistically significant from baseline to day 7 (4.55 ± 2.07 vs 3.44 ± 2.00; P < .0001) and day 15 (7.56 ± 2.40 vs 6.22 ± 2.55; P < .0001) in Hilo® group as compared to Daflon® group.
The patients treated with Hilo® capsules showed a significantly better improvement in total symptom score on both Day 7 & Day 15 when compared to Daflon® (P < .0001) ( Table 3 ).
Proportion of Patients Exhibiting Reduction in Total Symptom Score
The proportion of patients showing reduction of ≥ 50%, ≥ 75% and ≥ 80% in the total symptom score were evaluated and the two groups were compared using McNemar and exact (Liddell) test (Table 4) . 
Presence of Clinical Symptoms before and at the End of Treatment Period
At the baseline, the number of patients exhibiting the various clinical symptoms of hemorrhoids (bleeding, pain, itching, soiling, tenesmus, irritation after defecation, and constipation) were identified. At the end of the treatment (Day 15), the proportion of patients exhibiting the presence Table 3 . Difference between Hilo® and Daflon® treatment groups in improvement of total symptom score of hemorrhoids using Mann-Whitney U test Improvement in total symptom score with Hilo® and Daflon® Improvement on Day 7 Mean diff = 1.10 * 95% C.I. = 0.27 to 0.41 Improvement on Day 15 Mean diff = 0.23 of these clinical symptoms were evaluated. The proportion of patients exhibiting clinical symptoms in the two groups were compared at the end of the treatment using McNemar and exact (Liddell) test (Table 5) .
On comparing the two treatment groups, it was noted that a significantly less (P < .01) number of patients from Hilo® group exhibited the clinical symptoms of bleeding, pain, itching, soiling, tenesmus, irritation after defecation and constipation as compared to Daflon® on Day 7 as well as Day 15.
Improvement in Hemorrhoidal Grades
Hemorrhoidal assessment was performed as described in the study assessment section. At the end of study (Day 15), the improvement in the stage of hemorrhoids was significantly higher in the Hilo® group (Grade I: 74.75% of patients) as compared to Daflon® group (Grade I: 55.45% of patients) (Table 6 ).
At the end of the study, with Hilo® treatment 62 patients out of 83 (74.69%) from baseline of Grade II and Grade III combined exhibited improvement to Grade I. Similarly, with Daflon® treatment 44 patients out of 86 (total of Grade II and Grade III) improved to Grade I (51.16%). It was observed that a significantly a greater number of patients (P < .01) from Hilo® group showed improvement in hemorrhoidal grade as compared to Daflon® (Table 7 ). (Table 8) In Hilo® Group, 82.83% of patients assessed that the treatment with Hilo® made them 'A lot better' as compared to only 48.51% in Daflon® group.
Global Assessment of Therapy
In the Hilo® group, 20.2% of patients' treatment outcome was assessed as 'Excellent' by the investigators while in Daflon® group only 0.99% patients showed 'Excellent' outcome as per the investigator. 5.94% of patients in Daflon® group showed 'Poor' outcome at the end of study.
Adverse Events
There were no adverse events reported/observed in patients of either treatment groups during the course of the study.
DISCUSSION
A major component of a safe and effective therapy for hemorrhoids is the use of herbal products. Several herbal extracts containing flavonoids have been shown to improve microcirculation, capillary flow, and vascular tone, and strengthen connective tissue of the perivascular amorphous substrate. Flavonoid molecules also reduce inflammation by inhibiting prostaglandin and free radicals generated during the inflammatory response. The standard treatments for hemorrhoids are aimed toward removing the problem or palliating the disease.
Additionally, the low compliance associated with treatments such as hydrotherapy, mechanical compression therapy, and diet and lifestyle changes. This renders oral dietary supplementation an attractive option. The use of oral flavonoids offers an effective approach for the treatment of hemorrhoids. Early intervention with conservative therapies may prevent timeconsuming and expensive complications of hemorrhoids [16, 17] .
Flavonoids are considered as phlebotonics and were first described in the treatment of chronic venous insufficiency and edema. They appeared to be capable of increasing vascular tone, reducing venous capacity, decreasing capillary permeability, and facilitating lymphatic drainage as well as having anti-inflammatory effects [1] .
In an earlier study comparing Roidosanal® (standardized to contain not less than 7% of total catechins and epicatechins) and Daflon®, it was found that both the treatments are equally effective in improving anorectal conditions and the associated hemorrhoidal clinical symptoms.
No major adverse events were reported in the study with the use of either product [18] .
Daflon® tablets are a commercially available herbal medicine in India belonging to a similar category as that of Hilo®, hence it was used as comparator. In the present study, it was observed that patients treated with Hilo® showed a significant improvement in the clinical symptoms of bleeding, pain, itching, soiling, tenesmus, irritation after defecation and constipation (P < .0001) on day 7 as well as day 15 as compared to baseline. This is one of the most important aspect in the treatment of hemorrhoids when patient starts finding improvement in symptoms, the compliance towards prescribed drug increases and patient completes the full course of the medicine.
The mean total symptom score reduced by 4.55 on day 7 and by 7.56 on day 15 in the patients treated with Hilo®. The patients treated with Daflon® also showed a significant reduction in individual symptom score. The mean total symptom score reduced by 3.44 on day 7 and by 6.22 on day 15 in the patients treated with Daflon®. The improvement in total symptom score by both the treatments was compared using Mann-Whitney U test. Hilo® was found to be better in reducing the total symptom score on day 7 and day 15 as compared to Daflon® (P < .0001). These symptomatic improvement was corroborated by the proctoscopic findings of reduction in Grade of hemorrhoids.
Number of patients exhibiting clinical symptoms of hemorrhoids was significantly reduced in Hilo® group on Day 7 and day 15 as compared to Daflon® (P < .01). Proportion of patients exhibiting improvement in hemorhhoidal grades (from Grade II and Grade III to Grade I) was found to be greater in Hilo® group as compared to Daflon® (P < .01). This is an important aspect, as Grade III hemorrhoids, unlike Grade I and II hemorrhoids, do not usually present spontaneous improvement of the symptoms. These results are consistent with previously published data [18] . Thus a 15 days' course of Hilo can be recommended before proceeding for hemorrhoidectomy.
The current study has limitation of its smaller sample size. Further studies should be conducted to observe the impact of 15 days Hilo® therapy in avoiding the surgical intervention for the treatment of hemorrhoids.
CONCLUSION
In the present study, Hilo® was found to be better in improving the clinical symptoms of hemorrhoids as compared to Daflon®. Patients treated with Hilo® also showed improvement in the grades of hemorrhoids. There were no adverse events reported with either of the treatments. Hilo® is a safe and effective treatment for hemorrhoids.
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